{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Combined+Immunodeficiency+%28SCID%29&page=2",
    "query": {
      "condition": "Severe Combined Immunodeficiency (SCID)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Severe+Combined+Immunodeficiency+%28SCID%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T06:22:55.349Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001255",
      "title": "Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "ADA PBSC",
          "type": "DRUG"
        },
        {
          "name": "ADA Umbilical Cord Blood Cells",
          "type": "DRUG"
        },
        {
          "name": "Transduced Lymphocytes",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10,
      "start_date": "1990-09",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001255"
    },
    {
      "nct_id": "NCT00220766",
      "title": "Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunologic Deficiency Syndrome",
        "Agammaglobulinemia",
        "Severe Combined Immunodeficiency",
        "Wiskott-Aldrich Syndrome",
        "Common Variable Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified",
          "type": "DRUG"
        },
        {
          "name": "Dextrose, 5% in Water",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2002-08",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2009-09-25",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00220766"
    },
    {
      "nct_id": "NCT00794508",
      "title": "MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "ADA gene transfer",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Donald B. Kohn, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Month to 18 Years"
      },
      "enrollment_count": 10,
      "start_date": "2008-11",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00794508"
    },
    {
      "nct_id": "NCT02127892",
      "title": "SCID Bu/Flu/ATG Study With T Cell Depletion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "unrelated BM with T cell depletion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "unrelated cord blood",
          "type": "BIOLOGICAL"
        },
        {
          "name": "haplo BM with T cell depletion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "unrelated PBSC with T cell depletion",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Neena Kapoor, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 9,
      "start_date": "2007-01-02",
      "completion_date": "2016-08-01",
      "has_results": true,
      "last_update_posted_date": "2017-09-18",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02127892"
    },
    {
      "nct_id": "NCT03311503",
      "title": "Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency, X Linked",
        "Gene Therapy"
      ],
      "interventions": [
        {
          "name": "autologous CD34+ cell transduced with G2SCID vector",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "David Williams",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "5 Years",
        "sex": "MALE",
        "summary": "0 Years to 5 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2018-02-26",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311503"
    },
    {
      "nct_id": "NCT02999984",
      "title": "Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Due to ADA Deficiency"
      ],
      "interventions": [
        {
          "name": "Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)",
          "type": "GENETIC"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "PEG-ADA ERT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Days",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "30 Days to 17 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-12-16",
      "completion_date": "2019-09-26",
      "has_results": true,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02999984"
    },
    {
      "nct_id": "NCT03538899",
      "title": "Autologous Gene Therapy for Artemis-Deficient SCID",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "AProArt-CD34",
          "type": "DRUG"
        },
        {
          "name": "CliniMACS® CD34 Reagent System cell sorter device",
          "type": "DEVICE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Months and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-05-31",
      "completion_date": "2038-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03538899"
    },
    {
      "nct_id": "NCT02231710",
      "title": "Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Immune Deficiency Disorders",
        "Hemophagocytic Lymphohistiocytosis",
        "Inherited Bone Marrow Failure Syndrome",
        "Hemoglobinopathies",
        "Metabolic Disorders"
      ],
      "interventions": [
        {
          "name": "BPX-501 and Rimiducid",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "4 Months to 55 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-02",
      "completion_date": "2018-01",
      "has_results": true,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02231710"
    },
    {
      "nct_id": "NCT01821781",
      "title": "Immune Disorder HSCT Protocol",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Deficiency Disorders",
        "Severe Combined Immunodeficiency",
        "Chronic Granulomatous Disease",
        "X-linked Agammaglobulinemia",
        "Wiskott-Aldrich Syndrome",
        "Hyper-IgM",
        "DiGeorge Syndrome",
        "Chediak-Higashi Syndrome",
        "Common Variable Immune Deficiency",
        "Immune Dysregulatory Disorders",
        "Hemophagocytic Lymphohistiocytosis",
        "IPEX",
        "Autoimmune Lymphoproliferative Syndrome",
        "X-linked Lymphoproliferative Syndrome"
      ],
      "interventions": [
        {
          "name": "Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-04-29",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01821781"
    },
    {
      "nct_id": "NCT00579137",
      "title": "Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Disease",
        "Severe Primary Immunodeficiency Disorder",
        "Undefined T Cell Deficiency Disorder",
        "Wiskott-Aldrick Syndrome"
      ],
      "interventions": [
        {
          "name": "Campath -1H",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Anti-CD45",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3,
      "start_date": "2007-10",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-07-02",
      "last_synced_at": "2026-06-10T06:22:55.349Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00579137"
    }
  ]
}